Filing Overview
Phathom Pharmaceuticals, Inc. filed this Current Report on Form 8-K on October 29, 2019. The filing reports corporate charter and bylaw changes associated with the closing of the company’s initial public offering. It does not provide financial statements or operating results for a reporting period.
Business Context and Reporting Period
Phathom Pharmaceuticals is a Delaware corporation whose common stock trades on The Nasdaq Global Select Market under the symbol PHAT. The company identified itself as an emerging growth company.
Key Financial Metrics
- The filing does not provide revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity measures or other operating financial metrics.
- The filing does not state the IPO offering size, price, gross proceeds or net proceeds.
Material Changes and Corporate Governance
- The company filed an amended and restated certificate of incorporation with the Delaware Secretary of State effective in connection with the IPO closing.
- Authorized common stock increased to 400,000,000 shares.
- The company authorized 40,000,000 shares of undesignated preferred stock, issuable in one or more series at the board’s discretion.
- The board was classified into three classes, with staggered three-year terms.
- Directors may be removed only for cause and by the affirmative vote of holders of at least two-thirds of the outstanding voting capital stock.
- Stockholders may no longer act by written consent in lieu of a meeting.
- Certain derivative, fiduciary-duty and other specified actions must be brought exclusively in the Delaware Court of Chancery.
- Amended and restated bylaws became effective, including procedures for stockholder proposals and director nominations and provisions conforming to the restated certificate.
Guidance, Risks and Unusual Items
No financial guidance, operating outlook or management forecast is provided. The new governance provisions may affect stockholder voting, director elections, litigation venue and the board’s ability to issue preferred stock without a separate stockholder vote. The filing does not describe specific contingencies or unusual financial items.
Investor Verification Checklist
- Verify the IPO prospectus for offering price, share count, proceeds, underwriting discounts and dilution.
- Review the amended and restated certificate and bylaws attached as Exhibits 3.1 and 3.2 for the complete governance provisions.
- Assess the potential effect of the classified board, supermajority removal standard and preferred-stock authorization on shareholder rights.
- Confirm the company’s post-IPO cash position, liquidity, operating losses and financing needs in subsequent filings.